Sanofi is a research & development-driven, AI-powered global healthcare biopharma company dedicated to improving lives through innovative medicines and vaccines. As one of the world's leading pharmaceutical enterprises, Sanofi maintains a strong presence across multiple therapeutic areas and geographic markets.
Sanofi demonstrated robust financial performance in 2024, driven by strong sales growth and a commitment to R&D investment.
Full Year 2024 Performance:
- Annual Revenue: €44.29 billion, marking a 7.73% growth.
- Business EPS: €7.12 (+4.1% at CER), exceeding guidance.
- IFRS EPS: €4.59.
- Research & Development Expenses: Reached €7.4 billion, a 14.6% increase, aligning with company commitments.
Fourth Quarter (Q4) 2024 Performance:
- Net Sales: Reached €10.56 billion (compared to €9.68 billion in Q4 2023).
- R&D Investment: €2.25 billion in Q4 alone.
This strong revenue growth highlights the company's ability to capitalize on its diversified product portfolio and significant global market presence.
Sanofi's product portfolio is a key driver of its exceptional growth, with several blockbuster medications leading the charge.
- Dupixent: Achieved over €13 billion in sales, with an expected trajectory to reach approximately €22 billion in 2030.
- Beyfortus: Reached blockbuster status (€1.7 billion in sales) in its first full year, a significant milestone.
- Other Key Products: Lantus and Lovenox remain major revenue contributors.
- Key Therapeutic Sectors:
- Diabetes and Cardiovascular Diseases
- Oncology
- Immunology
- Multiple Sclerosis
- Rare Diseases and Rare Blood Disorders
- Vaccines
New launches contributed 11% of total sales in 2024, underscoring the success of Sanofi's innovation pipeline.
Sanofi maintains a strong and diversified international footprint, which provides stability and broad growth opportunities.
- United States: Generated approximately €18.5 billion in revenue in 2023.
- Europe: Generated about €10.4 billion in revenue in 2023.
Sanofi is actively pursuing strategic initiatives to sharpen its focus and enhance its leadership in the biopharma industry.
- Strategic Shift: In 2024, Sanofi announced its intention to sell a controlling stake in its consumer health business, Opella, to become a focused, science-driven biopharma company.
- 2025 Financial Guidance:
- Sales Growth: Anticipated to grow by a mid-to-high single-digit percentage at CER.
- Business EPS: Expected to see a strong rebound with growth at a low double-digit percentage at CER (before share buyback).
Sanofi's commitment to innovation is evident in its robust pipeline and significant R&D progress in 2024.
- Key Pipeline Achievements (2024):
- Positive Phase 3 Results: For new medicines like rilzabrutinib (rare diseases) and tolebrutinib (multiple sclerosis).
- Regulatory Milestones: Achieved 14 regulatory approvals for medicines and vaccines, 21 regulatory submission acceptances, and eight positive Phase 3 readouts, indicating strong and improving pipeline momentum.
Sanofi is dedicated to delivering consistent value to its shareholders through dividends and share buybacks.
- Dividend: The Board of Directors proposed a dividend of €3.92 for 2024, marking the 30th consecutive year of dividend increases.
- Share Buyback: Sanofi intends to execute a share buyback program of €5 billion in 2025 to further enhance shareholder value.
With its diversified product portfolio, strong financial performance, and unwavering commitment to innovation, Sanofi continues to solidify its position as a global leader in the pharmaceutical industry. Its focused strategy and operational excellence are poised to deliver consistent value to shareholders and advance healthcare worldwide.
